Filing Details

Accession Number:
0001179110-20-005046
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-22 17:39:10
Reporting Period:
2020-04-20
Accepted Time:
2020-04-22 17:39:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1730430 Kiniksa Pharmaceuticals Ltd. KNSA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1741382 W. Thomas Beetham C/O Kiniksa Pharmaceuticals, Ltd.
Clarendon House 2 Church Street
Hamilton D0 HM11
Evp & Chief Legal Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Shares Disposition 2020-04-20 47,423 $19.06 32,107 No 4 S Direct
Class A Common Shares Disposition 2020-04-21 1,563 $19.56 30,544 No 4 S Direct
Class A Common Shares Disposition 2020-04-21 955 $20.44 29,589 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale of Class A Common Shares reported in this From 4 was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on December 24, 2019.
  2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.00 to $19.17. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.07 to $20.05. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
  4. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $20.12 to $20.60. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.